Public Reporting
Accountable Care Public Reporting Information
Accountable Care Organization (ACO) Name and Location
Freedom Healthcare Alliance, LLC
8761 Dorchester Road
Suite 230
North Charleston, SC 29420
ACO Primary Contact
Primary Contact Name: Lissa Lara, CEO
Primary Contact Phone Number: 843-412-1590
Primary Contact Email Address: lissalara@qualityhealthcaredevelopment.com
Organizational Information
ACO PARTICIPANTS | ACO PARTICIPANT IN JOINT-VENTURE (Enter Y or N) |
Internal Medicine of Walterboro | N |
James T Martin Jr, MD | N |
Lake City Family Medicine, LLC | N |
Liberty Doctors, LLC | N |
Coastal Internal Medicine & Geriatrics | N |
Walterboro Adult & Pediatric Medicine | N |
ACO Governing Body
Member First Name | Member Last Name | Title/Position | Member’s Voting Power – Expressed as a percentage or number | Membership Type | ACO Participant TIN Legal Business Name/DBA, if Applicable |
Lissa | Lara | CEO | 16% | Other | N/A |
Hugh | Durrence | MD CMO Board Member | 13% | ACO Participant Representative | Liberty Doctors, LLC |
Donald | Hanna | MD Board Member | 13% | ACO Participant Representative | Liberty Doctors, LLC |
Douglas | Gleaton | MD Board Member | 13% | ACO Participant Representative | Liberty Doctors, LLC |
John | Forney | MD Board Member | 13% | ACO Participant Representative | Liberty Doctors, LLC |
David | Price | MD Board Member | 6% | Medicare Beneficiary Representative | N/A |
James | Martin Jr | MD Board Member | 13% | ACO Participant Representative | James T Martin Jr., LLC |
Jeffrey | Kramer | MD Board Member | 13% | ACO Participant Representative | Internal Medicine of Walterboro |
KEY ACO CLINICAL AND ADMINISTRATIVE LEADERSHIP:
Lissa Lara | ACO Executive |
Hugh Durrence | Medical Director |
John Park | Compliance Officer |
Kathrine Hill | Quality Assurance/Improvement Officer |
Associated committees and committee leadership:
Committee Name | Committee Leader Name and Position |
Finance Committee | Lissa Lara, CEO Hugh Durence, RPh, MD, Medical Director |
Quality Committee | Lissa Lara, CEO Hugh Durence, RPh, MD, Medical Director Kathrine Hill, Quality Assurance, Improvement Officer |
Compliance Committee | Lissa Lara, CEO Hugh Durence, RPh, MD, Medical Director John Park, Compliance Officer |
4Types of ACO Participants, or Combinations of Participants, That Formed the ACO:
- Primary Care Practice
- OBGYN
Shared Savings and Losses
Amount of Shared Savings/Losses:
-
- Fifth Agreement Period
- Performance Year 2023, $3,583,436.00
- Fourth Agreement Period
- Performance Year 2022, $3,429,097.03
- Third Agreement Period
- Performance Year 2021, $2,563,470.56
- Second Agreement Period
- Performance Year 2020, $2,960,193.32
- First Agreement Period
- Performance Year 2019, $921,888.00
- Fifth Agreement Period
Shared Savings Distribution:
Fifth Agreement Period : Performance Year 2023
-
- Proportion invested in infrastructure: 20%
- Proportion invested in redesigned care processes/resources: 4%
- Proportion of distribution to ACO participants: 76%
Fourth Agreement Period : Performance Year 2022
-
- Proportion invested in infrastructure: 5%
- Proportion invested in redesigned care processes/resources: 6%
- Proportion of distribution to ACO participants: 5%
Third Agreement Period : Performance Year 2021
-
- Proportion invested in infrastructure: 16%
- Proportion invested in redesigned care processes/resources: 9%
- Proportion of distribution to ACO participants: 74%
Second Agreement Period : Performance Year 2020
-
- Proportion invested in infrastructure: 30%
- Proportion invested in redesigned care processes/resources: 10%
- Proportion of distribution to ACO participants: 60%
First Agreement Period : Performance Year 2019
-
- Proportion invested in infrastructure: 37%
- Proportion invested in redesigned care processes/resources: 10%
- Proportion of distribution to ACO participants: 53%
Quality Performance Results
2023 Quality Performance Results:
Quality performance results are based on the CMS Web Interface collection type.
Measure # |
Measure Name |
Collection Type |
Reported Performance Rate |
Current Year Mean Performance Rate (SSP ACOs) |
Quality ID# 321 |
CAHPS for MIPS |
CAHPS for MIPS Survey |
6.87 |
6.25 |
Measure# 479 |
Hospital-Wide, 30-Day, All-Cause Unplanned Readmission (HWR) Rate for MIPS Groups |
Administrative Claims |
0.1631 |
0.1553 |
Measure# 484 |
Clinician and Clinician Group Risk-standardized Hospital Admission Rates for Patients with Multiple Chronic Conditions (MCC) |
Administrative Claims |
N/A |
35.39 |
Quality ID# 318 |
Falls: Screening for Future Fall Risk |
CMS Web Interface |
94.99 |
89.42 |
Quality ID# 226 |
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
CMS Web Interface |
62.22 |
79.29 |
Quality ID# 113 |
Colorectal Cancer Screening |
CMS Web Interface |
59.62 |
77.14 |
Quality ID# 112 |
Breast Cancer Screening |
CMS Web Interface |
71.01 |
80.36 |
Quality ID# 438 |
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
CMS Web Interface |
80.80 |
87.05 |
Quality ID# 370 |
Depression Remission at Twelve Months |
CMS Web Interface |
26.32 |
16.58 |
Quality ID# 001 |
Diabetes: Hemoglobin A1c (HbA1c) Poor Control |
CMS Web Interface |
13.57 |
9.84 |
Quality ID# 134 |
Preventive Care and Screening: Screening for Depression and Follow-up Plan |
CMS Web Interface |
80.22 |
80.97 |
Quality ID# 236 |
Controlling High Blood Pressure |
CMS Web Interface |
74.91 |
77.80 |
For previous years’ Financial and Quality Performance Results, please visit: data.cms.gov
Payment Rule Waivers
- Skilled Nursing Facility (SNF) 3-Day Rule Waiver:
- Our ACO uses the SNF 3-Day Rule Waiver, pursuant to 42 CFR § 425.612.
- Payment for Telehealth Services:
- Our ACO clinicians provide telehealth services using the flexibilities under 42 CFR § 425.612(f) and 42 CFR § 425.613.
Fraud and Abuse Waivers
- Parties to the arrangement: Freedom Health Alliance, LLC and Laboratory Corporation of America Holdings
- Date of arrangement: 12/1/2022
- Items, services, goods, or facility provided: Grants to incorporate data analytics platforms to facilitate care coordination and promote outcomes of care. Incorporate Lab Corp’s lab data into clinical data to provide a more robust view of the ACO’s patient population.
- Date and nature of any amendments to the arrangement,: January 1, 2024 – December 31, 2024, Renewal Agreement.
- ACO Participation Waiver:
- The following information describes each arrangement for which our ACO seeks protection under the ACO Participation Waiver, including any material amendment or modification to a disclosed arrangement.